Emerging classes of therapeutics—such as oligonucleotides, siRNA, and mRNA—offer new opportunities to modulate protein expression at the genetic or post-transcriptional level. These modalities hold great promise for addressing genetic disorders, rare diseases, and conditions previously considered undruggable. Primary hepatocytes are a well-established in vitro model for investigating liver biology, drug metabolism, hepatotoxicity, and disease mechanisms. Therefore, efficient transfection protocols of primary hepatocytes will be highly valuable for their broader application in high-throughput screening and gene modulation studies.
